Popular
Cognitive· Popular
In stockSelank
Selank Anxiolytic Peptide
Selank is supplied as 10mg lyophilised powder for laboratory research. Price is shown in your currency, and its Certificate from a named outside laboratory is published on this page. Not for human or veterinary use.
Size10mgPurity99.7%FormulaC33H57N11O9
Selank is a synthetic seven-amino-acid peptide developed at Russia's Institute of Molecular Genetics and modelled on tuftsin, an endogenous immunomodulatory fragment. It is investigated for its anxiolytic (anti-anxiety) profile and reported effects on GABAergic tone, BDNF expression and stress-circuit modulation in preclinical neuroscience studies.
€52
Quantity
HPLC verified
9–14 day shipping
Full COA
Worldwide delivery
About this compound
The research profile.
Selank is a synthetic heptapeptide built from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with a Pro-Gly-Pro tail. The tripeptide extension is the reason the molecule appears in the literature at all: it slows enzymatic degradation substantially compared with native tuftsin, which is what made systemic and intranasal study designs practical.
The published mechanism work is centred on GABAergic signalling rather than on direct receptor agonism. Cell-culture studies report that Selank shifts the expression of genes involved in GABAergic neurotransmission, and behavioural work in rodents describes it modifying the response to benzodiazepines rather than substituting for them. Separate reports describe effects on monoamine turnover, on enkephalin-degrading enzyme activity in serum, and on BDNF content in the hippocampus and prefrontal cortex — a spread of findings that reviewers characterise as a multi-target profile rather than a single defined binding site.
Because tuftsin is an immune-derived fragment, a parallel line of research examines cytokine expression under stress models. Reviewers of the field are explicit that the molecular account remains incomplete, and most of the clinical record sits in Russian-language psychiatry journals rather than in large multi-centre trials.
Published research
15 peer-reviewed studies on Selank are summarised in our research library, including 0 published since 2023 — with study designs, reported findings and what the evidence does not establish.
Read the Selank evidence baseFor research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.
Categorised as Cognitive — Neuropeptides for neuroscience research.
Dosing at a glance
What the literature reports.
For research and laboratory use only. Not for human consumption.
Route
Intranasal
Frequency
2–3x daily
Reported range
250–900 mcg
Protocol duration
2–4 weeks
250 mcgper day, divided across administrations900 mcg
Subcutaneous · Once daily · 250–500 mcg per administration · 2–4 weeks
Intranasal instillation is the route used in the published Russian clinical work, where a dilute aqueous solution was applied in divided daily portions across a two-to-four week course. Figures describe study protocols only.
Ranges reflect protocols reported in the published literature on Selank — see research citations.
Calculate a dilutionReconstitution & storage
From powder to solution.
- Step 01
Add 2 ml bacteriostatic water
Aim the stream at the vial wall rather than the powder.
- Step 02
Swirl gently — never shake
Rotate the vial until the solution runs clear. Agitation degrades the peptide.
- Step 03
Refrigerate at 2–8 °C
Reconstituted vials belong in the fridge, protected from direct light.
- Step 04
Use within 28 days
Discard any remainder once the stability window closes.
Lyophilised · −20 °CReconstituted · 2–8 °C, 28 days
A 10 mg vial in 2 ml of bacteriostatic water gives a 5 mg/ml solution — convenient for the low microgram amounts described in the literature.
Reconstitution calculator
10 mg vialmg
ml
mcg
250 mcg = 0.25 mg
Draw
5units · U-100 insulin syringe
- Concentration
- 5 mg/ml
- Draws per vial
- 40
- Cost per draw
- €1.30
For research and laboratory use only. Not for human consumption.
Laboratory arithmetic for Selank — enter the COA-verified vial content for exact figures. Not medical advice.
Effect timeline
Observed across the research window.
Milestones summarise findings reported in the cited studies. Outcomes vary across models and protocols.
Start
Acute administration studies
Rodent anxiety-model work reports measurable behavioural differences after single administrations, including altered responses when the peptide is paired with diazepam.
Week 1
Expression-level changes
Cell-culture and tissue studies describe shifts in the expression of genes tied to GABAergic neurotransmission within the first days of repeated exposure.
Week 2
Mid-course clinical comparisons
The Russian clinical literature reports interim rating-scale comparisons against an active benzodiazepine comparator around the two-week point of an intranasal course.
Week 4
Protocol end points
Published courses generally conclude between two and four weeks, where end-point comparisons and tolerability observations are recorded.
For research and laboratory use only. Not for human consumption.
Scientific research
The published evidence.
The dosing ranges and timeline milestones on this page summarise the peer-reviewed publications below.
References
- 01
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett (2018). PubMed · 30255741
- 02
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol (2017). PubMed · 28293190
- 03
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol (2017). PubMed · 28280289
- 04
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova (2014). PubMed · 25176261
- 05
[Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova (2015). PubMed · 26356395
Laboratory verification
One Certificate, published unaltered.
The Certificate is a test report from a named laboratory outside AKH, ordered by our manufacturer and shown here exactly as the laboratory issued it. A printed copy ships in every parcel.
- Batch
- 2026514
- Test date
- 16 May 2026
- Task ID
- #20265141
- Purity
- 99.7%
Results
Selank: 10.26 mg
Verified by Brown Institute of Biomolecular Research. Scan the full report for every measurement.
Product FAQ
Questions researchers ask.
Pairs well with
Frequently co-studied.
Compounds that appear alongside Selank in the research literature.
For research and laboratory use only. Not for human consumption.
Cognitive
